Market revenue in 2023 | USD 731.2 million |
Market revenue in 2030 | USD 2,219.7 million |
Growth rate | 17.2% (CAGR from 2023 to 2030) |
Largest segment | Product |
Fastest growing segment | Service |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Product, Service |
Key market players worldwide | AstraZeneca PLC, Caribou Biosciences Inc Ordinary Shares, Cellectis SA, CRISPR Therapeutics AG, Editas Medicine Inc, Roche Holding AG, PerkinElmer, Genscript Biotech Corp Class H, Danaher Corp, Intellia Therapeutics Inc, Lonza Group Ltd, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc, Cibus Inc Ordinary Shares - Class A, Beam Therapeutics Inc, Vertex Pharmaceuticals Inc, Addgene, EGenesis, Synthego, Mammoth Biosciences, Inscripta, PLANTEDIT, Hera Biotech, Origene Technologies, Recombinetics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to crispr and cas genes market will help companies and investors design strategic landscapes.
Product was the largest segment with a revenue share of 78.51% in 2023. Horizon Databook has segmented the China crispr and cas genes market based on product, service covering the revenue growth of each sub-segment from 2018 to 2030.
China accounted for a significant revenue share in Asia Pacific. As China holds a major share in the agriculture industry, researchers are continuously deploying CRISPR technology in this field. In addition, they are applying genome editing techniques in animals to facilitate human transplantation.
In recent years, China has introduced the largest number of clinical trials involving CRISPR technology in cancer treatment. As of December 2018, China holds 858 publicly available CRISPR patent applications, especially in agricultural and other industries.
Extensive research studies and a large number of patents are expected to drive revenue generation in China’s CRISPR market. In August 2016, researchers from the Sichuan University’s West China Hospital received approval from the hospital’s review board to conduct a CRISPR–Cas9 technique-based gene-editing trial in humans.
Horizon Databook provides a detailed overview of country-level data and insights on the China crispr and cas genes market , including forecasts for subscribers. This country databook contains high-level insights into China crispr and cas genes market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account